The authors of the paper said ivermectin, which saw its popularity increase during the COVID-19 pandemic, can kill mosquitoes that feed on people who have been treated with the drug. Due to the prevalence of mosquito-borne illnesses, ivermectin could be a novel solution for dealing with the transmission of malaria, they said.
“Ivermectin has shown great promise in reducing malaria transmission and could complement existing control measures.”
Researchers said that Kenyan children who received the anti-parasitic drug in the trial saw a 26 percent reduction in malaria incidence when compared with children who received a control drug, albendazole.
The trial, they said, involved more than 20,000 participants and more than 56,000 treatments. According to the study, the administration of ivermectin was also found to have produced no severe drug-related adverse effects, and only mild side effects were experienced by the participants.
“The findings suggest that ivermectin [mass drug administration] could be a valuable complementary strategy for malaria control, particularly in areas where mosquito resistance to insecticides is a growing concern,” Marta Maia, a researcher with the University of Oxford involved in the study, said in a statement.
During the pandemic, some researchers touted ivermectin as a means to treat COVID-19, although federal health officials have said that the drug is not effective in treating the virus.
The Food and Drug Administration has not cleared ivermectin to be used for COVID-19 and has advised against people using forms of ivermectin intended for animals.
Ivermectin’s potential side effects include nausea, vomiting, dizziness, loss of appetite, constipation, weakness, body shaking, chest discomfort, and more serious problems, including rash, hives, itching, blistering or peeling skin, confusion, sleepiness, disorientation, and coma.







